Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception

AIDS

Volumn 28, Issue 18, 2014, Pages 2771-2776

  Heffron, Renee ^a   Mugo, Nelly ^a,c   Were, Edwin ^d,k   Kiarie, James ^a,e   Bukusi, Elizabeth A ^a,b,f,n   Mujugira, Andrew ^a   Frenkel, Lisa M ^a   Donnell, Deborah ^a,g   Ronald, Allan ^h   Celum, Connie ^a   Baeten, Jared M ^a   Robert W Coombs, L F ⁱ   Kabwohe, Uganda ^k   Jinja, Uganda ^l   Hendrix, Craig W ⁱ   Lingappa, Jairam ⁱ   McElrath, M Juliana ⁱ   Kenya, Eldoret ^j   Fife, Kenneth ^k   Tumwesigye, Elioda ^l   Kampala, Uganda ^l   Elly Katabira, A R ^m   Kisumu, Kenya ^m   Mbale, Uganda ⁿ   Nairobi, Kenya ^e   Ndase, Patrick ^l   Katabira, Elly ^l   Cohen, Craig ⁿ   Wangisi, Jonathan ^e   Campbell, James ^e   Tappero, Jordan ^e   Thika, Kenya ⁿ   Tororo, Uganda ^e   Farquhar, Carey ^e   John Stewart, Grace ^e   Mugo, Nelly Rwamba ⁿ   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Clinical Research Centre   (Kenya)

^d MOI UNIVERSITY   (Kenya)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g USA   (United States)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ Center and Central Laboratories University of Washington Coordinating   (United States)

^j Moi University   (United States)

^k Kabwohe Clinical Research Center   (Uganda)

^l MAKERERE UNIVERSITY   (Uganda)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ The AIDS Support Organization   (Uganda)

more..

Author keywords

Depot medroxyprogesterone acetate; HIV 1 prevention; Hormonal contraception; Preexposure prophylaxis efficacy

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MEDROXYPROGESTERONE ACETATE; PLACEBO; TENOFOVIR; ANTIRETROVIRUS AGENT; CONTRACEPTIVE AGENT; DELAYED RELEASE FORMULATION;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADMINISTRATION AND DOSAGE; DELAYED RELEASE FORMULATION; HIV INFECTIONS; KENYA; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UGANDA;

ADULT; ANTI-RETROVIRAL AGENTS; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MEDROXYPROGESTERONE ACETATE; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UGANDA;

EID: 84927748449     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000493     Document Type: Article

References (30)

1. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21:1771-1777.
2. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010; 24:1778-1781.
3. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
4. McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 2013; 27:1001-1009.
5. Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: A systematic review of the epidemiologic evidence. AIDS 2013; 27:493-505.
6. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: A systematic review of the epidemiological evidence. Lancet Infect Dis 2013; 13:797-808.
7. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010; 31:79-97.
8. Achilles SL, Hillier SL. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS 2013; 27 (Suppl 1):S5-S15.
9. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013; 27:105-113.
10. Ngure K, Heffron R, Mugo NR, Celum C, Cohen CR, Odoyo J, et al. Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships. AIDS 2012; 26:513-518.
11. Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS 2011; 25:383.
12. United Nations. World contraceptive patterns 2013. New York: Department of Economic and Social Affairs, United Nations; 2013.
13. Gutin SA, Mlobeli R, Moss M, Buga G, Morroni C. Survey of knowledge, attitudes and practices surrounding the intrauterine device in South Africa. Contraception 2011; 83:145-150.
14. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587- 2599.
15. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399- 410.
16. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
17. World Health Organization. Hormonal contraceptive methods for women at high risk of HIV and living with HIV. Geneva: WHODepartment of Reproductive Health and Research; 2014.
18. Coleman J, Chaturveda A, Hendrix C, MTN-001 Protocol Team. Method of hormonal contraception is associated with lower tenofovir concentration in healthy women (MTN-001): implications for preexposure prophylaxis [abstract FRLBC03]. In: XIX International AIDS Conference. Washington DC; 2012.
19. Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, et al. Preexposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS 2014; 28:1825-1830.
20. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, et al. Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. PLoS One 2011; 6:e25828.
21. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: A substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med 2013; 10: e1001511.
22. Campbell MS, Mullins JI, Hughes JP, Celum C, Wong KG, Raugi DN, et al. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One 2011; 6:e16986.
23. Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R, Chen YQ, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis 2011; 204:1918-1926.
24. Baeten JM, for the Partners PrEP Study Team. Single agent TDF versus combination FTC/TDF PrEP among heterosexual men and women [abstract]. In: Conference on Retroviruses and Opportunistic Infections 2014. Boston; 2014.
25. Mehta CR, Patel NR. Exact logistic regression: Theory and examples. Stat Med 1995; 14:2143-2160.
26. Friend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies: Products in development. Antiviral Res 2013; 100 (Suppl):S39-S47.
27. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
28. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preexposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003) [abstract #26LB]. In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta; 2013.
29. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women's experiences with oral and vaginal preexposure prophylaxis: The VOICE-C qualitative study in Johannesburg, South Africa. PLoS One 2014; 9:e89118.
30. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: Adherence patterns and factors associated with adherence to a daily oral study product for preexposure prophylaxis. J Acquir Immune Defic Syndr 2014; 66:324-331.